Pfizer's Lung Cancer Drug Is Extending Survival Rates and Stopping Cancer Spread

NEWS Health News Pfizer's Lung Cancer Drug Is Extending Survival Rates and Stopping Cancer Spread By Kayla Hui, MPH Published on June 07, 2024 Fact checked by Nick Blackmer Print Illustration by Zoe Hansen for Verywell Health Key Takeaways An ongoing study showed that 60% of lung cancer patients who took a drug called Lorbrena remained alive and disease-free after five years, compared to 8% of those who were treated with Xalkori.The CROWN study offers the longest progression-free survival results …